Talk:Biovest

I think the content of this article is highly questionable. Nobody really knows what has become of Biovaxid and - after a lot of legal and financial calamities - of the company. It simply sounded to good in the beginning and some scientists gave their name to promote the product. Later it became clear that the good results of the trials were not reliable.

• • • • — Preceding unsigned comment added by Atemkristall (talk • contribs) 18:11, 30 April 2020 (UTC)

Why do you want to delete the article? The company may be important because it is developing a new class of drug called a cancer vaccine. The first cancer vaccine was recently approved by a competitor (Dendreon's Provenge drug). Just like Rituximab was the first anti-cancer monoclonal antibody approved for cancer (in 1997), Dendreon's Provenge for Prostate Cancer is the first FDA approved cancer vaccine. This company, Biovest, has already completed a phase III trial for it's follicular lymphoma drug BiovaxID, which is also a cancer vaccine.

If you want me to add more to this article, I will when I have time.

Article Name

I'm pretty sure "Biovaxid" should be the primary article, and "Biovest" a redirect to it, rather than the other way round as it is at present. What do you think? Thparkth (talk) 01:27, 2 May 2010 (UTC)

Not sure that makes sense... Biovaxid is a product of biovest... having biovest redirect to biovaxid is like having walmart GE redirect to ultrasound... right now it's their prime product but still nonsensical —Preceding unsigned comment added by 69.153.131.53 (talk) 06:29, 4 May 2010 (UTC)

Response

Feel free to change the redirects or anything else. I just wanted to create a basic page about BiovaxID and Biovest.

Contested deletion

This article should not be speedily deleted for lack of asserted importance because I added BiovaxID intro, manufacturing, data, indications, and company patents. — TiantongQ (talk) 07:35, 3 December 2011 (UTC)